JP2005526051A - Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物 - Google Patents

Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物 Download PDF

Info

Publication number
JP2005526051A
JP2005526051A JP2003572509A JP2003572509A JP2005526051A JP 2005526051 A JP2005526051 A JP 2005526051A JP 2003572509 A JP2003572509 A JP 2003572509A JP 2003572509 A JP2003572509 A JP 2003572509A JP 2005526051 A JP2005526051 A JP 2005526051A
Authority
JP
Japan
Prior art keywords
ptp
compound
hydrogen
exosite
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003572509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526051A5 (https=
Inventor
ケネス バー，
ブルース ファー，
スティッグ ハンセン，
クリスチャン ウィエスマン，
Original Assignee
サネシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サネシス ファーマシューティカルズ， インコーポレイテッド filed Critical サネシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005526051A publication Critical patent/JP2005526051A/ja
Publication of JP2005526051A5 publication Critical patent/JP2005526051A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003572509A 2002-03-01 2003-02-26 Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物 Withdrawn JP2005526051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36147502P 2002-03-01 2002-03-01
US10/374,539 US6784205B2 (en) 2002-03-01 2003-02-25 Compounds that modulate the activity of PTP-1B and TC-PTP
PCT/US2003/005950 WO2003073987A2 (en) 2002-03-01 2003-02-26 Compounds that modulate the activity of ptp-1b and tc-ptp

Publications (2)

Publication Number Publication Date
JP2005526051A true JP2005526051A (ja) 2005-09-02
JP2005526051A5 JP2005526051A5 (https=) 2006-04-13

Family

ID=27791680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572509A Withdrawn JP2005526051A (ja) 2002-03-01 2003-02-26 Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物

Country Status (6)

Country Link
US (2) US6784205B2 (https=)
EP (1) EP1534264A4 (https=)
JP (1) JP2005526051A (https=)
AU (1) AU2003217766A1 (https=)
CA (1) CA2477119A1 (https=)
WO (1) WO2003073987A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
US6974681B1 (en) * 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
CA2551909C (en) * 2004-02-12 2011-10-11 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ569329A (en) 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
WO2009091609A1 (en) * 2008-01-18 2009-07-23 Genaera Corporation A method for treating rapamycin induced diabetes-like syndrome using trodusquemine
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014113407A2 (en) * 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
US10618932B2 (en) 2017-02-21 2020-04-14 Arizona Board Of Regents On Behalf Of Arizona State University Method for targeted protein quantification by bar-coding affinity reagent with unique DNA sequences

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703407B1 (en) * 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
US6498151B2 (en) * 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU2001268951A1 (en) * 2000-07-07 2002-01-21 Novo-Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)

Also Published As

Publication number Publication date
WO2003073987A3 (en) 2005-03-31
WO2003073987A2 (en) 2003-09-12
AU2003217766A1 (en) 2003-09-16
US20040147596A1 (en) 2004-07-29
CA2477119A1 (en) 2003-09-12
EP1534264A2 (en) 2005-06-01
EP1534264A4 (en) 2007-06-13
US6784205B2 (en) 2004-08-31
US20030195247A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AU2007298929B2 (en) Novel genes related to glutaminyl cyclase
JP2005526051A (ja) Ｐｔｐ−１ｂおよびｔｃ−ｐｔｐの活性を調節する化合物
JP2024037770A (ja) Ｓａｒｍ１阻害剤
MX2012005342A (es) Uso de derivados benzo-heterociclico para prevenir y tratar el cancer o para inhibir metastasis de cancer.
CZ20013833A3 (cs) Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
WO1999046232A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP7062643B2 (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
WO2009152735A1 (zh) 一类组蛋白去乙酰化酶抑制剂及其应用
JP2023527942A (ja) 粒子状グアニリルシクラーゼ受容体ａのエンハンサー
US20210317115A1 (en) Inhibitors of kidney-type glutaminase, gls-1
JP2002531500A (ja) Ｍｙｔ１キナーゼ阻害剤
US20230144901A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
WO2000033842A1 (en) Myt1 kinase inhibitors
WO2012083092A2 (en) Bi-dentate compounds as kinase inhibitors
JP2021506975A (ja) 線維症を処置するための化合物および組成物
CA2598607A1 (en) Methods and compositions for cell-cycle regulation
JP2002531503A (ja) Ｍｙｔ１キナーゼ阻害剤
US11628159B2 (en) Cell-protective compounds and their use
KR20130108876A (ko) Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
EP4428121A1 (en) Modulators of sortilin activity
AU2012241108B2 (en) Novel genes related to glutaminyl cyclase
US8063082B2 (en) Certain chemical entities, compositions, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070717